Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.40 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.38 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 4/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19788379 | 1.00 | LMNA (0.42) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL17002538 | 0.87 | SIRT2 (0.45) | TDP1P2RY2P2RY4P2RY6SIRT5 | |
| SCHEMBL15627693 | 0.87 | PDE4D (0.44) | TDP1CA1CA2CXCR3SIRT5 | |
| SCHEMBL19788376 | 0.87 | SIRT2 (0.45) | TDP1P2RY2P2RY4P2RY6SIRT5 | |
| SCHEMBL19788378 | 0.86 | LMNA (0.43) | LMNATDP1CA1CA2CXCR3 | |
| SCHEMBL15627682 | 0.86 | LMNA (0.43) | LMNATDP1CA1CA2CXCR3 | |
| SCHEMBL15627674 | 0.86 | LMNA (0.43) | LMNATDP1CA1CA2CXCR3 | |
| SCHEMBL19788383 | 0.86 | LMNA (0.43) | LMNATDP1CA1CA2CXCR3 | |
| SCHEMBL15627691 | 0.86 | LMNA (0.43) | LMNATDP1CA1CA2CXCR3 | |
| SCHEMBL19788380 | 0.86 | LMNA (0.43) | LMNATDP1CA1CA2CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160184459-A1 | CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2016-06-30 | — | — | US | disclosed |
| US-20150224208-A1 | NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2015-08-13 | — | — | US | disclosed |
| WO-2014047199-A1 | NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2014-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184459-A1 | CANCER CELL SPECIFIC IMAGING PROBES AND METHODS OF USE | OR10J3, CCR3, GPR3 | LMNA 3752/4885THRB 520/4885MTOR 3974/4885 |
| US-20150224208-A1 | NOVEL PRODRUGS FOR SELECTIVE ANTICANCER THERAPY | NR4A3, ORC3, NTSR1 | LMNA 4644/4885THRB 722/4885MTOR 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.